NCT07725172
Radiation Therapy and Thymus Function in Young Women With Breast Cancer
At risk: Primary completion moved at least 32 days later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Start date pushed from Sep 2026 to Nov 2026
- Primary and study completion pushed from Sep 2029 to Nov 2029
- Notable Recruitment opened
- Eligibility criteria expanded, about 9 words
- Study description expanded, about 7 words
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Level of signal joint T cell Receptor Exclusion Circles (sjTREC) in peripheral blood T cells
Timeframe: baseline
Level of CD4+ recent thymic emigrant (RTE) cells in participant blood samples
Timeframe: baseline
Level of CD4+ RTE cells in participant blood samples
Timeframe: at the end of RT, about 5 weeks
Effect of adjuvant radiotherapy treatment dose on levels of sjTREC-containing T cells
Timeframe: 6 months post RT
Effect of adjuvant radiotherapy treatment fractionation on levels of sjTREC-containing T cells
Timeframe: 6 months post RT
Effect of adjuvant radiotherapy treatment fractionation on levels of CD4+ RTE cells
Timeframe: 6 months post RT
Effect of adjuvant radiotherapy treatment dose on levels of CD4+ RTE cells
Timeframe: 6 months post RT
Arms and interventions
Radiation Therapy
Up to 100 Breast cancer patients receiving radiation therapy
No Radiation Therapy
Up to 25 Breast cancer patients NOT receiving radiation therapy as control
Procedures: Blood draw for the laboratory assessment
Sites
1 site in 1 country
- Duke Cancer CenterDurham, North Carolina, United States